Change in Orion Group Executive Management Board: change in Orion's group-level functions

22 Mar 2024
www.globenewswire.com
Executive Change
Change in Orion Group Executive Management Board: change in Orion's group-level functions
ORION CORPORATION
STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS
22 MARCH 2024 at 12.30 EET
Change in Orion Group Executive Management Board: change in Orion's group-level functions
The following change will take place in Orion's group-level functions: the Corporate Strategy and Program Management (CSPMO) unit will become part of the Finance and Corporate Business Development unit.
The change will strengthen the steering of the Group and create a more unified approach to support Orion's business operations. As a result of the change, SVP Virve Laitinen will step down from the Orion Executive Management Board and will report to the Chief Financial Officer of the Orion Group as a Head of CSPMO. The change will take effect as of 1 April 2024.
Liisa Hurme
President and CEO Olli Huotari
SVP, Corporate Functions
Contact person:
Liisa Hurme, President and CEO
tel. +358 50 966 2874
liisa.hurme@orion.fi
Publisher:
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.


For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.